Venture Capital News Daily
   Your Source for Venture Capital and Private Equity Financings
   Massinvestor/VC News Daily      
   Venture Capital News Daily on RSS Venture Capital News Daily on Facebook Venture Capital News Daily on Twitter
VC DATABASE   /   MOBILE APP  /  CELEBRITY VCs   /   VENTURE TRACKR   /   ARCHIVE   /   ABOUT US
VC-funded Company:


ImmusanT
One Kendall Square, Suite B2004
Cambridge, MA 02139
Phone: 617-299-8399
http://www.immusant.com/

ImmusanT is focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that aim to improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The company is developing Nexvax2, a therapeutic vaccine for celiac disease, and a companion diagnostic and monitoring tool to improve celiac disease management. ImmusanT's targeted immunotherapy discovery platform can be applied to a variety of epitope-specific autoimmune diseases. Founded in 2010, ImmusanT is backed by Vatera Healthcare Partners.

Key Contact
NameTitleE-Mail
Leslie WilliamsCEO


Funding Events
DateAmountTypeInvestors
12/22/14$12,000,000Series B Vatera Healthcare Partners
11/14/17$40,000,000Series C ARCH Venture Partners
Vatera Healthcare Partners
 
Massinvestor/VC News Daily
617-620-4606


© 2018 Massinvestor, Inc.